医药公司开始了阿联第二期试验,使用含有多克索鲁比辛的微针贴片治疗基底细胞癌. Medicus Pharma began a UAE Phase 2 trial using a microneedle patch with doxorubicin to treat basal cell carcinoma.

药剂师已开始在阿联酋进行第2阶段的SKNJCT-004试验,治疗第一名病人,使用非侵入性微型针片,其中含有用于巴萨细胞癌的多克斯罗比素。 Medicus Pharma has initiated its Phase 2 SKNJCT-004 trial in the UAE, treating the first patient with a non-invasive microneedle patch containing doxorubicin for basal cell carcinoma. 该研究招收了六个阿联酋地点的36名病人,将对安慰剂进行两剂治疗测试。 The study, enrolling up to 36 patients across six UAE sites, will test two doses of the treatment against a placebo. 它遵循美国类似试验的有希望的结果,支持该公司争取林业发展局批准的途径。 It follows promising results from a similar U.S. trial and supports the company’s path toward FDA approval. Medicus公司还获得了设在联合王国的Antev公司,扩大了输油管线,有可能对前列腺癌和尿液保留进行新的治疗。 Medicus also acquired UK-based Antev, expanding its pipeline with a potential new treatment for prostate cancer and urinary retention.